1. A method for controlling a plasma processing apparatus that comprises:
a vacuum vessel in which plasma is generated;
a first RF power supply, a second RF power supply and a third RF power supply provided outside the vacuum vessel;
a first electrode disposed either inside or outside the vacuum vessel to which a first RF voltage from the first RF power supply is supplied;
a second electrode disposed inside the vacuum vessel, having an upper surface on which a sample is mounted, and to which a second RF voltage from the second RF power supply is supplied; and
a phase control unit for controlling a phase difference between the second RF voltage and a third RF voltage from the third RF power supply;
wherein the controlling method comprises the steps of:
supplying a predetermined power from the first RF power supply to ignite plasma;
after confirming ignition of plasma, supplying a predetermined power respectively from the second RF power supply and the third RF power supply; and
when starting power supply from the second RF power supply and the third RF power supply, fixing the phase to a predetermined phase angle using a preset mode without carrying out phase control, and after a matching operation has stabilized, starting the phase control.
2. A method for controlling a plasma processing apparatus that comprises:
a vacuum vessel in which plasma is generated;
a first RF power supply, a second RF power supply and a third RF power supply provided outside the vacuum vessel;
a first electrode disposed either inside or outside the vacuum vessel to which a first RF voltage from the first RF power supply is supplied;
a second electrode disposed inside the vacuum vessel, having an upper surface on which a sample is mounted, and to which a second RF voltage from the second RF power supply is supplied; and
a phase control unit for controlling a phase difference between the second RF voltage and a third RF voltage from the third RF power supply;
wherein the controlling method comprises the steps of:
controlling the phase difference between the RF voltage of the second electrode and the third RF voltage having a same frequency using a signal source other than a phase signal, disposed between the second electrode and an RF radiation unit that is capacitively coupled with plasma; and
when removing a deposition film inside the vacuum vessel, controlling the phase difference according to an amount of the deposition film.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed is:
1. A method of treating adiposity or obesity comprising administering either concurrently or within about one hour an amount of lipase inhibitor effective to reduce the absorption of dietary fat by one tenth to about one third of the amount of fat consumed and a non-absorbable lipophilic polysaccharide in an amount from about 2 to 10 percent of the weight of the consumed fat, wherein each of the lipase inhibitor and the lipophilic polysaccharide are administered either prior to, or within one hour after, the consumption of a meal contain fat.
2. The method of claim 1 wherein the lipase inhibitor is present in an amount effective to reduce such fat absorption by one fifth to about one third of the amount of fat consumed.
3. The method according to claim 1 wherein the lipophilic polysaccharide is present in an amount of 4 to 8 percent of weight of the consumed fat.
4. The method according to claim 1 wherein the lipase inhibitor is selected from the group consisting of orlistat, lipstatin, tetrahydrolipstatin and esterastin.
5. The method according to claim 4 wherein the lipase inhibitor is orlistat and is administered in an amount from 25 to 120 mg per fat-containing meal.
6. The method according to claim 1 wherein the lipophilic polysaccharide is a member selected from the group consisting of chitosan, sulfated alginic acid, sulfated pectin, sulfated amylopectin, sulfated chitin, sulfated chitosan, sulfated dextran and sulfated nonsoluble plant cellulose.
7. The method according to claim 6 wherein the lipophilic polysaccharide is chitosan or a modified Chitosan and is administered after a fat-contain meal in an amount from 4 to 8 percent of the weight of the consumed fat.
8. The method according to claim 7 wherein the modified Chitosan is administered in an amount from 5 to 8 percent of the weight of the consumed fat and the modified Chitosan is modified with a sufficient number of organic acyl groups to cause the modified Chitosan to absorb or associate both lipids and water and to form a substantially homogenous gel with oil and water.
9. A method according to claim 1 wherein the lipase inhibitor and the lipophilic polysaccharide are administered in the same composition or dosage formulation.
10. A method according to claim 1 wherein the lipase inhibitor and the lipophilic polysaccharide are administered in separate dosage formulations.
11. A pharmaceutical composition for treating adiposity or obesity comprising an amount of lipase inhibitor effective to reduce the absorption of dietary fat by one tenth to about one third of the amount of fat consumed and a non-absorbable lipophilic polysaccharide in an amount from about 2 to 10 percent of the weight of the consumed fat, and said polysaccharide is capable of absorbing fat and dispersing the fat in an aqueous solution.
12. The composition according to claim 11 wherein the lipase inhibitor is present in an amount effective to reduce such fat absorption by one fifth to about one third of the amount of fat consumed.
13. The composition according to claim 11 wherein the lipophilic polysaccharide is present in an amount of 4 to 8 percent of weight of the consumed fat.
14. The composition according to claim 11 wherein the lipase inhibitor is selected from the group consisting of lipstatin, tetrahydrolipstatin, esterastin and tetrahydroesterastin.
15. The composition according to claim 11 wherein the lipase inhibitor is orlistat and is present in an amount from 25 to 120 mg.
16. The composition according to claim 11 wherein the lipophilic polysaccharide is a member selected from the group consisting of chitosan, sulfated alginic acid, sulfated pectin, sulfated amylopectin, sulfated chitin, sulfated chitosan, sulfated dextran and sulfated nonsoluble plant cellulose.
17. The composition according to claim 16 wherein the lipophilic polysaccharide is a modified chitosan and is present in an amount an amount from 4 to 8 percent of the weight of the consumed fat, wherein the modified Chitosan is capable of binding fat and then dispersing the absorbed fat in an aqueous solution.
18. A composition according to claim 11 wherein the lipase inhibitor and lipophilic polysaccharide are present in weight proportions of from 1:4 to 1:10.
19. A composition according to claim 19 wherein the lipase inhibitor and lipophilic polysaccharide are present in weight proportions of from 1:5 to 1:8.
20. A composition according to claim 18 wherein having from 25 to 75 mg of the lipase inhibitor and from 100 to 750 mg of the lipophilic polysaccharide.
21. A method according to claim 1 comprising administering a lipophilic polysaccharide comprising from 250 to 1000 mg of a modified chitosan prior to consuming a fat containing meal, administering concurrently with said fat containing meal, or within one hour thereafter, a separate dosage formulation of a lipase inhibitor comprising from 25 to 120 mg of orlistat, and adminstering in a separate dosage formulation currently with said fat containing meal, or within one hour thereafter an amount of chitosan to provide a overall amount of chitosan which is from 2 to 10 percent by weight of the fat consumed per meal, wherein the modified Chitosan is capable of absorbing fat and dispersing the absorbed fat in an aqueous solution.
22. The method according to claim 21, wherein for said fat containing meal the amounts of orlistat and modified chitosan administered are in weight proportions of from 1:4 to 1:10.
23. The method according to claim 21, wherein for said fat containing meal the amounts of orlistat and modified chitosan administered are in weight proportions of from 1:5 to 1:8.
24. The method according to claim 21, wherein for said fat containing meal the amounts of orlistat and modified chitosan administered are in the weight proportions of 1:6.
25. A method according to claim 21, wherein for said fat containing meal the amount of orlistat adminstered is 120 mg and the amount of modified chitosan administered is 1000 mg.